ORO. A. Rakhmanina

O. A. Rakhmanina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. A. Rakhmanina has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epilepsy in patients with Down syndrome (literature review and clinical cases)

    by Mariya Yu. Bobylova, Бобылова Мария Юрьевна, S. G. Burd, Бурд С. Г., T. R. Tomenko, Томенко Т. Р., O. A. Rakhmanina, Рахманина О. А., Z. K. Gorchkhanova, Горчханова З. К., et al.

    An overview of the literature and clinical cases of epilepsy in Down syndrome (DS) is presented. Epilepsy in DS has a bimodal distribution with two peaks: before 5 years of age and after 40 years. In childhood, the most common epileptic syndrome is infantile epileptic spasms syndrome. First-line treatment includes vigabatrin and corticosteroids. The second peak of epilepsy occurs after the age of 40 and is associated with the coexistence of epilepsy and Alzheimer’s disease, which is known as late-onset myoclonic epilepsy in DS, the seizure semiology of which is similar to that of juvenile myoclonic epilepsy. Clinical cases of patients with infantile epileptic spasms syndrome and DS successfully treated with vigabatrin are presented. Comorbidities in DS include a high prevalence of obstructive sleep apnea syndrome, increased carbonic anhydrase type 2 activity, and the presence of myoclonic seizures similar to those in juvenile myoclonic epilepsy. These features support the use of sultiame as a pathogenetically justified drug for the treatment of epilepsy in patients with AD. A clinical case of a patient with DS is presented, in whom sultiame demonstrated high efficacy and good tolerability, as well as a positive impact on development and behavior

  • The use of Perampanel suspension in clinical practice for children and adolescents with epilepsy: a compilation of insights from Russian experts

    by A. M. Pivovarova, Yu. A. Aleksandrov, Yu. V. Bazhanova, M. V. Barkhatov, O. V. Belyaev, T. E. Volskaya, E. K. Gorbunova, Z. K. Gorchkhanova, A. I. Grechikhina, D. I. Gukosyan, et al.

    Objective : to evaluate the efficacy and tolerability of perampanel suspension (Fycompa®) in real-world clinical practice among children and adolescents with epilepsy in a cohort of Russian patients. Material and methods. A retrospective multicenter analysis was conducted of depersonalized data from 80 patients from 27 centres (40 boys, 40 girls) aged between 4–18 years (mean age 8.2 years) with various forms of epilepsy who received perampanel suspension (PER) as adjunctive therapy. Inclusion criteria were a verified diagnosis of epilepsy consistent with the drug's approved indications, and the availability of data on seizure frequency prior to treatment and after 1–3 months of therapy. To assess efficacy after 3–6 months, data were used from patients who continued treatment and had corresponding records. Statistical analysis was performed using descriptive statistical methods. The primary outcome measures were changes in seizure frequency after 1–3 and 3–6 months of therapy, the proportion of responders, the rate of remission, and adverse events (AEs). Results. After 1–3 months of treatment, the highest efficacy was observed in isolated bilateral tonic-clonic seizures (BTCS; remission – 78.5%, overall response rate – 89.2%) and generalised tonic-clonic seizures (GTCS; remission – 71.4%, overall response rate – 100%). For focal seizures (FS) without progression to BTCS, remission was 38%, and the overall response rate was 71%. In FS progressing to BTCS, remission was recorded in 37.5% of patients, with an overall response rate of 62.5%. In patients with a combination of these seizure types and other types of seizures, a reduction in the frequency of concomitant seizures was also observed. At the 3–6-month stage, an additional response (remission or a ≥50% reduction in seizure frequency) was observed in only a small proportion of patients (for example, additional remission in FS without BTCS was observed in 10.3% of patients). The drug demonstrated reasonably good tolerability: AEs were reported in 16.3% of patients after 1–3 months, and the need for discontinuation was 2.5%. Conclusion. The PER suspension is well tolerated and effective in children aged 4 years and older with FS, with or without progression to BTCS, and in children aged 7 years and older with GTCS, including patients weighing less than 30 kg. The liquid formulation allows for precise dose titration and is convenient to administer, particularly in patients with dysphagia.

  • Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)

    by V.I. Guzeva, S.I. Kutsev, A.S. Petrukhin, S.O. Ayvazyan, E.D. Belousova, S.G. Burd, I.V. Volkov, O.V. Globa, M.YU. Dorofeeva, N.A. Ermolenko, et al.

    Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.


  • Open Access

    Dynamics of management of monogenic epilepsies, developmental and epileptic encephalopathies in routine clinical practice

    by О. A. Rakhmanina, I. V. Volkov, Т. R. Tomenko, O. I. Shestakova, О. К. Volkova

    Background. There is no doubt that genetic testing should be one of the main studies in modern clinical diagnosis of epileptic syndromes.Aim. To describe and compare the spectrum of detected gene mutations in patients with epilepsy and developmental and epileptic encephalopathies (DEE) over the last 3 years of clinical practice of neurologists-epileptologists, including: analysis of diagnosed epileptic syndromes, timing of etiological diagnosis, treatment options and effectiveness.Materials and methods. A multicenter retrospective study including patients of any age and gender with epilepsy or DEE (with the obligatory presence of epileptic seizures) and verified gene mutations. The analysis was carried out as of 2020 and 2023. Over a three-year period, the number of data received in the study increased and amounted to 100 and 205 patients, respectively, 87–90 % of whom were children under 18 years of age.Results and discussion. Over a three-year period, the number of genes with mutations increased from 67 to 98 variants. The clear leader remains mutations in the SCN1A gene. In practice, the number of referrals for whole exome sequencing has doubled from 9 to 18.6 % and the proportion of patients with mutation confirmation by Sanger sequencing has doubled from 32 % to 50.7 %. Up to 68 % of patients with a confirmed gene mutation are patients with one or another variant of DEE. Approaches to therapy with antiepileptic drugs have not undergone significant changes. but the volume of alternative methods decreased slightly from 52 to 45 %, with an emerging trend toward an increase in the effectiveness of therapy (an increase in the percentage of patients with no seizures from 46 to 54 %).Conclusion. Analytical processing and expansion of experience in the etiological diagnosis of monogenic epilepsies and DEE is reflected in a more targeted selection and effectiveness of therapy for this category of patients.


  • Open Access

    Independent Occurrence of Two Cases of Lennox — Gastaut Syndrome and Neurofibromatosis in the Family: A Clinical Observation

    by O. A. Rakhmanina, E. V. Levitina, E. B. Khramova, D. M. Khairetdinova, Дж. И. Лебедева

    Developmental and epileptic encephalopathies (DEE) are the most difficult problem in epileptology. Lennox — Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy with onset in childhood, manifested by: frequent polymorphic seizures, including tonic axial ones; severe cognitive impairment; slow activity (with a frequency of The purpose of this work was to describe a familial case of LGS in two siblings.Materials and methods. A retrospective description of the medical history of 3 siblings born in a consanguineous marriage was performed.Results and discussion. There was a similarity in the course of the disease in the two brothers, absolute resistance to drug antiepileptic therapy and temporary effectiveness of hormonal therapy for LGS with a decrease in the duration of the effect from course to course. In addition, the rare parallel existence in this family of another autosomal dominant disease — neurofibromatosis type 1 — is shown.Conclusion. A detailed description of LGS within one family will not only expand doctors’ knowledge of this disease and the difficulties of its treatment, but also improve understanding of the genetic mechanisms of the development of DEE.

  • Open Access

    Experience of using zonisamide in children in routine clinical practice (a multicenter study)

    by M. Yu. Bobylova, I. V. Volkov, O. K. Volkova, I. S. Bakhtin, D. I. Gukosyan, O. A. Rakhmanina, M. V. Barkhatov, I. G. Shchukina, Yu. Yu. Kalinina, K. Yu. Mukhin, et al.

    Background. The problem of antiepileptic therapy in children remains highly relevant due to the insufficient efficacy of standard drugs, adverse events, and limitations of clinical guidelines.Aim. To assess the efficacy, tolerability, and continuation of zonisamide (Zonegran) therapy in children with epilepsy.Materials and methods. This retrospective multicenter study was conducted in epileptology centers in various regions of the Russian Federation, including Moscow, Novosibirsk, Krasnodar, Tyumen, Krasnoyarsk, Voronezh, Ryazan). We included 340 patients under the age of 18 (202 boys and 138 girls) with various epileptic syndromes receiving zonisamide (mean age was 10.63 years). Zonisamide was administered to patients with the following epileptic syndromes: age-dependent self-limited focal epilepsy of childhood (n = 49; 14 %) structural focal epilepsy (n = 102; 30 %), focal epilepsy of childhood with structural brain changes and benign epileptiform discharges of childhood visualized at electroencephalography (n = 38; 11.2 %), idiopathic generalized epilepsy (n = 23; 6.7 %), developmental and epileptic encephalopathies (n = 44; 12.9 %) (including developmental and epileptic encephalopathies with spike-and-wave activation during sleep (n = 23; 6.7 %)), Lennox–Gastaut syndrome and infantile epileptic spasms syndrome (n = 32; 9.4 %), genetic epilepsy with generalized and focal seizures (n = 81; 23.8 %). The type of the seizures was distributed as follows: focal motor (n = 205), bilateral tonic-clonic (n = 192), generalized (n = 197), including generalized convulsive (n = 44), tonic (n = 70), atonic (n = 2), myoclonic (n = 26), epileptic spasms (n = 36), absence seizures (n = 19). One patient could have more than one type of seizures. Magnetic resonance imaging demonstrated some changes in 185 patients, whereas 117 patients had no magnetic resonance imaging changes. Thirty-eight patients did not undergo magnetic resonance imaging as they had no indications to it. The most common structural epileptogenic changes were the consequences of perinatal lesions manifesting as cystic-gliotic transformation, atrophy (125 cases in total); less common changes included focal cortical dysplasia, developmental abnormalities (such as polymicrogyria, lissencephaly, holoprosencephaly), mesial temporal sclerosis, and tumors. Zonegran (zonisamide) as an additional therapy was administered at a dose of 3–8 mg/kg/day (mean dose 5 mg/kg/day) to 321 patients.Results. Zonegran (zonisamide) therapy was effective in 257 (75.6 %) of patients; remission was achieved in 174 patients (67.7 %), while reduced seizure frequency (50 % and greater) was registered in 83 patients (32.3 %). A total of 72 patients (21.2 %) reported no adverse events. Twenty participants (5.8 %) had some adverse events; in 4 cases, they were resolved after dosage decrease; in 16 cases, treatment with zonisamide was discontinued.Conclusion. Zonegran (zonisamide) is effective for comprehensive treatment of both focal and generalized epilepsy in children*.

  • Encephalopathy GNAO1

    by M.YU. Bobylova, I.V. Volkov, E.V. Gumennik, O.A. Rachmanina, M.O. Abramov, O.K. Volkova, T.S. Bayborina, A.S. Petrukhin

    РЕЗЮМЕ ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить клиническую картину всех обнаруженных в Российской Федерации на момент исследования пациентов с энцефалопатией GNAO1, редким аутосомно-доминантным заболеванием, связанным с мутацией гена GNAO1. МАТЕРИАЛ И МЕТОДЫ Публикация является результатом мультицентрового исследования, объединившим данные эпилептологических центров Москвы, Новосибирска, Санкт-Петербурга, Нижнего Новгорода, Тюмени. Включены 9 пациентов в возрасте от 2 до 19 лет с 4 мутациями. Соотношение пациентов мужского и женского полов 5:4. РЕЗУЛЬТАТЫ У 8 пациентов (5 — с мутацией c.607G>A (p.Gly203Arg), 1 — c.155A>G (Gln52Arg), 1 — c.485G>A (p.Arg162Gln)) отмечался вариант эпилептической энцефалопатии, энцефалопатии развития, у 1 пациентки — ДЦП-подобный вариант с наличием торсионной дистонии без клинических проявлений синдрома GNAO1 эпилепсии (мутация c.713A>G (p.Asp238Gly)). Эпилептические приступы у 8 детей с эпилептической энцефалопатией GNAO1 в 100% дебютировали на 1-м месяце жизни, став самым ранним симптомом заболевания. Задержка двигательного развития отмечалась в 100% случаев. Психическое развитие не пострадало только в случае дистонического варианта. Гиперкинезы в виде дистонии, хореоатетоза и баллизма присоединялись позже — с 2 до 8 мес. Они протекали более тяжело, чем эпилепсия, и составляли ядро клинической картины у всех детей. У 4 пациентов с мутацией c.607G>A (p.Gly203Arg) развивались повторные «дистонические бури», которые были резистентны к большинству препаратов. ЗАКЛЮЧЕНИЕ Эпилепсия при GNAO1 трудно поддается лечению, но можно достичь временной или полной ремиссии. Эффективные медикаментозные стратегии для лечения гиперкинезов в настоящее время не разработаны. Желательно расширение показаний для хирургической терапии гиперкинезов при данном синдроме.


  • Open Access

    The first combined Russian experience of using perampanel in children and adolescents with epilepsy in everyday clinical practice

    by O. A. Rakhmanina, I. V. Volkov, O. K. Volkova, Yu. A. Aleksandrov, M. V. Barkhatov, I. S. Bakhtin, G. M. Berezhnaya, S. R. Boldyreva, E. N. Bochkova, E. K. Gorbunova, et al.

    Background. Real world data help to provide more information on the effects and tolerability of therapy. However, data on the use of perampanel in Russian population of children remain limited.Aim. To conduct a retrospective analysis of perampanel efficacy and tolerability in children and adolescents with epilepsy in real clinical practice.Materials and methods. A total of 106 children aged 4–18 years receiving perampanel as part of combination therapy for epilepsy were observed at 18 centers. Seizure frequency at 1–3, after 6 and 12 months of treatment, presence and type of adverse events (AEs) were analyzed. The main assessed efficacy parameters were seizure control, significant (≥50 %) decrease in seizure frequency. All other outcomes (50 % decrease, no change or increased seizure frequency) were considered to be no effect. The assessed safety parameters were the percentage of patients with or without AEs and the percentage of perampanel withdrawals due to AEs.Results. We defined 3 age groups for comparison: children 4–6, 7–11 and 12–17 years old. Perampanel efficacy was 69 % (seizure control – 23.6 %, ≥50 % decrease in seizure frequency – 45.3 %). The mean duration of the effect was 7.3 ± 4.1 months. No significant difference in efficacy between age groups was found. However, some greater efficacy of perampanel was noted in adolescents: absence of effect in the form of remission or significant decrease in seizures frequency was noted only in 25.5 %, with 40 % in children 4–11 years old. Among those with inefficacy, 3.8 % reported seizure aggravation. AEs occurred in only 23 % of patients, with the least frequent occurrence in adolescents (11.8 %) and the most frequent in children aged 7–11 years (40 %). The most frequent AEs was sluggishness and/or drowsiness. Discontinuation of perampanel due to AEs was required in 7.6 %.Conclusion. Perampanel has demonstrated high efficacy and good tolerability in real clinical practice among children from 4 years of age and adolescents with partial (focal) and secondary generalized seizures. The AEs that developed were not serious and very rarely led to withdrawal of the therapy. The results are comparable to those of phase III studies and previous real-world data. The usage of perampanel in children with primary generalized seizures should be further investigated.


  • Sporadic hemiplegic migraine (rare case in clinical practice)

    by E. V. Levitina, O. A. Rakhmanina, I. A. Lebedev

    The article describes the peculiarities of a rare disease – hemiplegic migraine in three patients (two boys aged 7 and 15 and a girl of 12 years old). The family history of migraine was not burdened. Attack symptoms were almost identical: hemiparesis, dysphasia, and headache. The electroencephalograms, magnetic resonance imaging in all patients not presented signs brain dysfunction. Analysis of the literature data has been carried out. Thediagnostic criteria for hemiplegic migraine, its differential diagnosis is described. The considered description increases the awareness of doctors on the issue, which is very rare in the practice of pediatrician and neurologist.

  • Epilepsy and other phenotypic features of X-linked intellectual disability caused by the mutations in the KIAA2022 gene

    by R.G. Gamirova, A.I. Barkov, V.A. Shaimuchametova, N.G. Liukshina, I.V. Volkov, T.R. Tomenko, O.A. Rachmanina, O.I. Shestakova, E.A. Gorobets

    To study the literature data and a series of our cases regarding the epilepsy clinic, electroencephalographic changes and other phenotypic features in X-linked intellectual disability (ID) caused by KIAA2022 mutations. We analyzed the anamnesis of the disease, using medical records from different Russian medical organizations, as well as the results of the genealogical anamnesis, clinical, genetic, electroencephalographic (EEG) and neuroimaging (brain MRI ) examinations of 7 patients (5 girls and 2 boys aged 5 to 13 years) with a confirmed diagnosis of X-linked ID caused by KIAA2022 mutations, in whom the clinical picture of the underlying disease was combined with epilepsy. The main common phenotypic features of patients with X-linked ID caused by the KIAA2022 mutations are mental retardation, lack of phrasal speech, motor developmental delay, and dysmorphism. The prominent epilepsy characteristics are myoclonic, atonic seizures with nods, flinches, body propulsions, atypical absences, and diffuse discharges «spike-polyspike-slow wave» on the EEG. No pathognomonic brain changes were found on MRI. In many cases, the absence of the effect of antiepileptic therapy was noted. The described cases of X-linked ID in combination with epilepsy show that this disease can be seen in males as well as in females, epilepsy is rather characterized by generalized seizures, and it is pharmacoresistant in many cases. There is a need for further research on this rare genetic syndrome.